Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Trial ID or NCT#
NCT04260698
Status
NOT RECRUITING
Purpose
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Official Title
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Eligibility Criteria
Ages Eligible for Study: Older than 12 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * Patients must be at least 12 years of age* Applicable disease criteria* Patients must have one or two partially HLA-matched CBUs* Back-up stem cell source* Sufficient physiological reserves* Females of childbearing potential agree to use appropriate method of contraception* Signed written informed consent
Exclusion Criteria:
- * Extensive bone marrow fibrosis* Donor specific anti-HLA antibodies* Pregnancy* Medically unsuitable for transplant
Contact us to find out if this trial is right for you.
Contact
Khanh Nguyen
650-721-2372
View on ClinicalTrials.gov
